Comparative specificity and sensitivity of NS1-based serological assays for the detection of flavivirus immune response

Flaviviruses are relevant animal and human pathogens of increasing importance worldwide. The similarities of the initial clinical symptoms and the serological cross-reactivity of viral structural antigens make a laboratory diagnosis of flavivirus infection problematic. The main aim of the present st...

Full description

Saved in:
Bibliographic Details
Published inPLoS neglected tropical diseases Vol. 14; no. 1; p. e0008039
Main Authors Mora-Cárdenas, Erick, Aloise, Chiara, Faoro, Valentina, Knap Gašper, Nataša, Korva, Miša, Caracciolo, Ilaria, D’Agaro, Pierlanfranco, Avšič-Županc, Tatjana, Marcello, Alessandro
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 01.01.2020
Public Library of Science (PLoS)
Subjects
Online AccessGet full text
ISSN1935-2735
1935-2727
1935-2735
DOI10.1371/journal.pntd.0008039

Cover

More Information
Summary:Flaviviruses are relevant animal and human pathogens of increasing importance worldwide. The similarities of the initial clinical symptoms and the serological cross-reactivity of viral structural antigens make a laboratory diagnosis of flavivirus infection problematic. The main aim of the present study was the comparative specificity and sensitivity analysis of the non-structural protein NS1 as an antigen to detect flavivirus antibodies in sera from exposed individuals. A strategy for the purification of native recombinant non-structural protein 1 of representative flaviviruses including tick-borne encephalitis, West Nile, Zika and dengue virus was developed. The immunological properties of the purified antigens were analyzed using sera of immunized mice and of infected individuals in comparison with standard commercial assays. Recombinant NS1 protein was confirmed as a valuable option for the detection of flavivirus antibodies with reduced cross-reactivity and high sensitivity offering additional advantages for the detection of vaccine breakthrough cases.
Bibliography:new_version
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
The authors have declared that no competing interests exist.
ISSN:1935-2735
1935-2727
1935-2735
DOI:10.1371/journal.pntd.0008039